Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Cortes

Showing results (171-180 of 231) with videos related to

Pageof 24
Sort By:
NPJ Breast Cancer|May 21, 2021
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter studyLinda T Vahdat, Peter Schmid, Andres Forero-Torres, et al.
NPJ Breast Cancer|July 8, 2017
The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international groupMarion Maetens, David Brown, Alexandre Irrthum, et al.
NPJ Breast Cancer|September 12, 2024
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBCSeock-Ah Im, Javier Cortes, David W Cescon, et al.
Journal of the National Cancer Institute|December 9, 2023
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355David W Cescon, Peter Schmid, Hope S Rugo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast CancerTiffany A Traina, Kathy Miller, Denise A Yardley, et al.
European Journal of Hospital Pharmacy : Science and Practice|February 18, 2020
The economic burden of metastatic breast cancer in SpainBegoña Bermejo de Las Heras, Javier Cortes Ramon Y Cajal, Elena Galve Calvo, et al.
Lancet (London, England)|December 6, 2020
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortes, David W Cescon, Hope S Rugo, et al.
Breast Cancer Research and Treatment|March 22, 2017
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancerJosé Baselga, Serafin M Morales, Ahmad Awada, et al.
Melanoma Research|February 27, 2018
Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapyMaria Gonzalez-Cao, Clara Mayo de Las Casas, Nuria Jordana Ariza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2014
High HER2 expression correlates with response to the combination of lapatinib and trastuzumabMaurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, et al.
Pageof 24

Showing results (171-180 of 231) with videos related to

Sort By:
Pageof 24
NPJ Breast Cancer|May 21, 2021
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter studyLinda T Vahdat, Peter Schmid, Andres Forero-Torres, et al.
NPJ Breast Cancer|July 8, 2017
The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international groupMarion Maetens, David Brown, Alexandre Irrthum, et al.
NPJ Breast Cancer|September 12, 2024
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBCSeock-Ah Im, Javier Cortes, David W Cescon, et al.
Journal of the National Cancer Institute|December 9, 2023
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355David W Cescon, Peter Schmid, Hope S Rugo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast CancerTiffany A Traina, Kathy Miller, Denise A Yardley, et al.
European Journal of Hospital Pharmacy : Science and Practice|February 18, 2020
The economic burden of metastatic breast cancer in SpainBegoña Bermejo de Las Heras, Javier Cortes Ramon Y Cajal, Elena Galve Calvo, et al.
Lancet (London, England)|December 6, 2020
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortes, David W Cescon, Hope S Rugo, et al.
Breast Cancer Research and Treatment|March 22, 2017
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancerJosé Baselga, Serafin M Morales, Ahmad Awada, et al.
Melanoma Research|February 27, 2018
Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapyMaria Gonzalez-Cao, Clara Mayo de Las Casas, Nuria Jordana Ariza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2014
High HER2 expression correlates with response to the combination of lapatinib and trastuzumabMaurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, et al.
Pageof 24